Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of delayed access to specialist heart valve treatment has on (a) avoidable unscheduled hospitalisations, (b) deaths on waiting lists and (c) other patient outcomes.

No specific assessment has been made of the potential impact of delayed access to specialist heart valve disease (HVD) treatment on avoidable unscheduled hospitalisations, deaths on waiting lists, or other patient outcomes.

Cutting waiting times, including for cardiology services, is a key priority for the Government. The cardiology waiting list decreased from 412,164 in September 2024 to 393,400 in September 2025, although this data includes estimates for missing data.

Cardiology is a priority specialty for significant transformation, as outlined in the Elective Reform Plan. The ambition is, where possible and clinically appropriate, to increase specialist care closer to home, and outside of hospitals so that hospital capacity is freed up, enabling patients' timely access to care, as well as improving outcomes.

NHS England has committed to optimising pathways of care for patients with HVD, including earlier detection and improved treatment pathways. To achieve this, the NHS England Cardiac Programme has established an expert advisory group and carried out work including, in 2024/25, providing targeted funding for pathway improvement projects. These included projects that focussed on improving referral processes and local diagnostic pathway provision, as well as fast-tracking patients on valve disease pathways.

To accelerate progress towards the Government’s ambition to reduce premature deaths from heart disease and stroke by 25% within a decade, we will publish a new cardiovascular disease modern service framework in 2026.